Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to -$8.2 million.

  • Aytu Biopharma's Other Non Operating Income fell 37334.22% to -$8.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$12.1 million, marking a year-over-year decrease of 24397.09%. This contributed to the annual value of -$1.7 million for FY2025, which is 5746.75% up from last year.
  • Latest data reveals that Aytu Biopharma reported Other Non Operating Income of -$8.2 million as of Q4 2025, which was down 37334.22% from $3.8 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Other Non Operating Income peaked at $3.8 million during Q3 2025, and registered a low of -$9.9 million during Q2 2025.
  • Moreover, its 5-year median value for Other Non Operating Income was $593000.0 (2022), whereas its average is -$249300.0.
  • In the last 5 years, Aytu Biopharma's Other Non Operating Income skyrocketed by 557750.0% in 2022 and then crashed by 77395.76% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's Other Non Operating Income stood at -$257000.0 in 2021, then skyrocketed by 645.91% to $1.4 million in 2022, then crashed by 141.13% to -$577000.0 in 2023, then soared by 622.7% to $3.0 million in 2024, then tumbled by 373.34% to -$8.2 million in 2025.
  • Its last three reported values are -$8.2 million in Q4 2025, $3.8 million for Q3 2025, and -$9.9 million during Q2 2025.